Business Context and Reporting Period
This Form 8-K Current Report was filed by Trevi Therapeutics, Inc. on August 9, 2021. The filing discloses the appointment of a new Chief Financial Officer and details the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change reported is the appointment of Lisa Delfini as Chief Financial Officer and principal financial officer, effective August 9, 2021. This replaces the prior financial leadership structure.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, market outlook, or general management commentary regarding business operations. It details the following specific terms of the new CFO's employment:
- Base Salary: $330,000 annualized.
- Annual Incentive Bonus: Up to 35% of the annualized base salary.
- Equity Grant: Option to purchase 100,000 shares of common stock at the closing price on August 9, 2021. Vesting is 25% on the first anniversary, with the remainder vesting monthly (1/48th per month) thereafter.
- Separation Benefits: Eligible under the Executive Separation Benefits and Retention Plan. If employment terminates prior to August 9, 2022, severance is limited to specific circumstances with a calculation period of three months.
- Indemnification: Ms. Delfini will enter into the Company's standard indemnification agreement covering expenses, judgments, fines, and settlements arising from her service.
Investor Verification Checklist
- Verify the full text of the Offer Letter agreement when filed as an exhibit to the Form 10-Q for the quarter ended June 30, 2021.
- Review the Executive Separation Benefits and Retention Plan (filed previously on September 24, 2019) to understand the specific conditions for the limited severance eligibility during the first year.
- Confirm the exercise price of the 100,000 stock options based on the closing price of TRVI on August 9, 2021.
- Monitor future filings for any changes to the Company's financial reporting standards or internal controls resulting from the new CFO's tenure.